Literature DB >> 18550885

More on ovarian insufficiency with imatinib.

Saul Malozowski, Lawrence Nelson, Karim Anton Calis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18550885     DOI： 10.1056/NEJMc080707

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Will imatinib compromise reproductive capacity?

Authors:  Alberuni M Zamah; Michael J Mauro; Brian J Druker; Kutluk Oktay; Merrill J Egorin; Marcelle I Cedars; Mitchell P Rosen
Journal:  Oncologist       Date:  2011-09-23

Review 2.  Endocrine side effects of broad-acting kinase inhibitors.

Authors:  Maya B Lodish; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2010-08-16       Impact factor: 5.678

3.  Lapatinib‑induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro.

Authors:  Qiuyue Liao; Xue Feng; Xi Li; Ge Chen; Jing Chen; Bin Yang; Kezhen Li; Jihui Ai
Journal:  Oncol Rep       Date:  2020-06-24       Impact factor: 3.906

4.  The Tyrosine Kinase Inhibitor Sunitinib Affects Ovulation but Not Ovarian Reserve in Mouse: A Preclinical Study.

Authors:  Valérie Bernard; Justine Bouilly; Piet Kramer; Nadège Carré; Martin Schlumberger; Jenny A Visser; Jacques Young; Nadine Binart
Journal:  PLoS One       Date:  2016-04-01       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.